AOD-9604 is a synthetic fragment of human growth hormone that is marketed online as a fat-burning peptide. Mouse studies support the idea. Human results do not. A small early trial suggested a modest effect, and the larger follow-up trial reported no statistically significant weight loss compared with placebo. No FDA-approved AOD-9604 product exists for obesity. If you want medically supervised weight loss, there are options with far stronger human evidence.
This guide explains what AOD-9604 is, what the trials found, how to read the before-and-after photos and dosing claims you see online, and what MOTS-c adds to the picture.
TL;DR
- AOD-9604 is a 16-amino-acid fragment of human growth hormone (amino acids 176-191) that increased fat breakdown in mice.
- In humans, a 12-week early trial showed modest weight loss, but the 24-week, 536-person follow-up did not beat placebo, and development stopped.
- Safety data in trials looked similar to placebo, but that does not make the peptide effective, and no FDA-approved product exists for obesity.
- MOTS-c has no established human weight-loss evidence. Before-and-after posts for either peptide are not evidence.
- Doctor-led GLP-1 care is the better-studied route. We offer it from $149 per month.
Table of Contents
- What AOD-9604 is and why it drew attention
- What the human trials found
- Is AOD-9604 safe?
- FDA status: not approved for obesity
- How to read AOD-9604 results and before-and-after photos
- What about MOTS-c?
- Perspective: where we stand
- What has stronger evidence for weight loss
- How to decide
- FAQ
- Sources
What AOD-9604 is and why it drew attention
The name stands for "anti-obesity drug 9604." It is a synthetic 16-amino-acid fragment of human growth hormone, amino acids 176-191, designed to keep growth hormone's fat-burning signal while leaving out its other effects. That was the appeal: fat loss without the blood sugar and tissue-growth concerns tied to full growth hormone.
The animal data is where the excitement began. A 2001 peer-reviewed study in Endocrinology found that the fragment reduced body weight and body fat in obese mice and increased their sensitivity to fat breakdown. The authors saw higher beta-3 adrenergic receptor expression but concluded that the fat-loss action was not directly mediated through that receptor. So even in mice, the exact mechanism was unsettled.
Mouse results often fail in people. Rodents differ from humans in metabolism, receptor biology and how they respond to peptides. The question is what happened when AOD-9604 was tested in people.
What the human trials found
The human record is short and mixed. According to a summary of the clinical studies, an early 12-week phase 2a trial of about 300 people reported modest weight loss versus placebo. In that trial, the 1 mg daily oral dose was associated with about 2.6 kg lost, against 0.8 kg on placebo.
The result did not hold. The same summary reports that the larger 24-week phase 2b trial, called OPTIONS, enrolled 536 people and found no statistically significant weight loss compared with placebo. Development for obesity was discontinued after that.
Two details are worth understanding:
- The early trial had an inverted dose response. Higher doses did not produce better results than lower ones. That pattern can occur in real pharmacology, but it is also a common sign of a chance finding. The confirmatory trial did not reproduce it.
- A 2.6 kg difference is small. Even taken at face value, it is under 6 lb over 12 weeks, and it was measured in a trial that did not replicate.
If you track your own results on any medication, baseline and follow-up bloodwork gives you data instead of guesses. Understanding how weight loss clinic labs are used helps explain why a clean dataset, not an anecdote, is what separates a real effect from a chance one.
Is AOD-9604 safe?
This is the part where AOD-9604 looks better. A pooled safety analysis of six randomized, double-blind, placebo-controlled trials with about 900 participants reported a safety and tolerability profile indistinguishable from placebo. It found no treatment-related serious adverse events, no significant rise in IGF-1 and no adverse effect on carbohydrate metabolism.
A clinical summary submitted to the FDA also reports no anti-AOD-9604 antibodies in the patients tested, and no related withdrawals or serious adverse events.
Read that carefully. A drug that is safe in a trial setting and does not work is still not a weight-loss treatment. These data come from pharmaceutical-grade product given in a controlled study. They say little about unregulated powders, "research-grade" vials or products of unknown purity sold online. If you have a medical condition, take other medications or are pregnant or nursing, talk with your own physician before using any peptide not approved for your use.
FDA status: not approved for obesity
The nomination document submitted to the FDA states that no FDA-approved product is available for obesity. AOD-9604 is also not a vitamin or a standard supplement.
Compounding is the other route people ask about. In September 2023, the FDA placed AOD-9604 on its Category 2 list of bulk drug substances, which restricts pharmacies from compounding it. Regulatory lists are revised from time to time, so check the FDA's current bulk drug substances page before assuming a product is permitted.
In practice, this means the AOD-9604 sold on many websites is labeled "for research use only." That label is a signal that the product is not made, tested or prescribed as a medicine.
How to read AOD-9604 results and before-and-after photos
Searches for AOD-9604 before-and-after pictures far outnumber searches for the trial data. That gap is where marketing lives. Here is how to judge what you see.
Photos and testimonials are not trial data
A single photo has no control group. You cannot tell what else changed: diet, training, lighting, posture, other medications or simply time. People who post dramatic results are also the ones who choose to post. Those with no change stay silent.
In a placebo-controlled trial, even the placebo group lost weight (0.8 kg in the early trial above). That is why people on a peptide often see changes and credit the product.
"Spot fat loss" is not supported
Some sellers claim that injecting AOD-9604 near the belly or thighs burns fat in that area. We found no human trial that supports local fat reduction, and no credible mechanism for it. A peptide injected under the skin circulates; it does not stay in one place.
Watch for the red flags
- Words like "research-grade" next to dosing instructions for humans.
- Claims of "significant reduction in body fat" with no trial cited.
- No mention of the phase 2b trial that failed to beat placebo.
- Pages that sell the peptide and also write the "review."
We also see sites quoting dosing for weight loss. Any dose you read online is a number from a sales page or forum, not from an approved label. The early trial used 1 mg per day by mouth. That figure was never confirmed as effective, and we do not recommend self-dosing from it.
What about MOTS-c?
MOTS-c is a peptide encoded in mitochondrial DNA. It is discussed in the same circles as AOD-9604 because of animal data on insulin sensitivity and fat accumulation. For people, the picture is thinner. One clinical evidence review describes MOTS-c as a research-stage compound with no established clinical weight-loss evidence in humans, and AOD-9604 clinical evidence as negative and largely inactive.
So searches for MOTS-c weight-loss or fat-loss results lead to the same answer: there are no human trial results to show. Any "results" you find are individual claims.
Perspective: where we stand
We get asked about peptides every week, and we treat the question seriously. Peptides can have a role in medicine, and we offer compounded peptides under clinician oversight. But the claim that a peptide helps you lose weight has to meet the same standard as any other medication claim: a controlled human trial that beats placebo.
AOD-9604 did not clear that bar. We would rather tell you that plainly than sell you hope. Our approach is to start with what has been shown to work, build a plan around your health history and keep a clinician involved as your dose and goals change. Dietitian visits and care coaching sit alongside the medication because medication alone rarely carries a plan through months of change.
If you want to read more on how we rank the evidence, our guides on how peptides help weight loss and fat-burning peptides ranked set out the same standard for each compound.
— Flexible
What has stronger evidence for weight loss
If your goal is meaningful, lasting weight loss, the medications with the best human data are GLP-1 based prescriptions. They have been tested in large, long randomized trials and, depending on the product, carry FDA approval for weight management. Our overview of FDA-approved weight loss medications lists what is on the market, and the guide to types of weight loss prescriptions explains how they differ.
Not everyone is a candidate. A clinician has to review your history, medications and goals. Our candidacy guide covers who is typically considered and who is not.
How we help
Dayla Health provides doctor-led, personalized GLP-1 care online, with no insurance required and shipping nationwide. Your plan includes a clinician evaluation, medication, care coaching and dietitian visits. Published prices, paid monthly:
| Plan | Price |
|---|---|
| Oral GLP, liposomal (needle-free) | from $149 per month |
| GLP-1 Microdose | from $159 per month |
| GLP-1 Injection | from $179 per month |
| dayla GLP-1 program | $299 per month |
You complete an online intake, a clinician reviews it and, if you are approved, your medication ships to you. Cancellation is flexible. See the plans and current pricing to compare injection, microdose and needle-free options.
How to decide
Use these questions before you spend money on any weight-loss peptide:
- Is there a controlled human trial? If the only evidence is mice, forums or a seller's page, treat the claim as unproven.
- Did it beat placebo in the larger trial? An early positive result that fails in a bigger study is a warning, as with AOD-9604.
- Is it approved or legally prescribed? "Research use only" means no one has vouched for the product's quality or your use of it.
- Is a clinician following you? Dose changes, side effects and other medications need a professional who knows your history.
- Does the plan include nutrition and support? Results hold better when eating and activity change with the medication.
For a wider look at the category, our weight loss peptides comparison goes through the main compounds side by side.
FAQ
Does AOD-9604 work for weight loss?
The evidence says probably not. It reduced fat in mice, and an early human trial showed a small effect. The larger 24-week trial found no statistically significant difference from placebo, and development for obesity stopped.
What is the right AOD-9604 dosage for weight loss?
There is no established dose, because the compound was never approved for weight loss. The early trial tested oral doses including 1 mg daily, but it did not replicate. Dosing you see online comes from sellers and forums, not from a label, so ask your own physician before using it.
Is AOD-9604 FDA-approved?
No. An FDA submission states that no approved product is available for obesity. The agency has also placed it on a list that restricts pharmacy compounding.
Are AOD-9604 before-and-after photos real?
Some may be real photos, but they prove nothing about the peptide. They lack a control group and ignore diet, training and the placebo effect. No human trial supports spot fat loss.
Is MOTS-c better for fat loss?
No human trial shows that it is. It remains a research-stage compound with animal and lab data only. If you want evidence-backed treatment, speak with a clinician about prescription GLP-1 options.
Sources
- Effects of Human GH and Its Lipolytic Fragment (AOD9604), Endocrinology 2001
- Peptides for Obesity: Clinical Evidence Review
- AOD-9604 Research: Clinical Studies and Evidence
- Safety and Tolerability of the Hexadecapeptide AOD9604
- FDA docket submission on AOD-9604 (regulations.gov)
- FDA Adds Several Peptides to Category 2 Bulks List
- Weight loss clinic labs and usable research data